INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33601, 29075, 'Bortezomib', 'Diabetes Mellitus', 'Hypoglycemia and hyperglycemia was reported during clinical trials in diabetic patients in treatment with oral hypoglycemics and receiving bortezomib.  Patients on oral antidiabetic agents may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication when using bortezomib.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33602, 5164, 'Bortezomib', 'Liver Diseases', 'Cases of acute liver failure and other hepatic reactions such as hepatitis, increases in liver enzymes, and hyperbilirubinemia have been reported in patients receiving bortezomib.  Monitoring is recommended and caution should be used when using bortezomib in patients with hepatic impairment.  The exposure of bortezomib is increased in patients with moderate and severe hepatic impairment, and starting dose should be reduced in those patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33603, 15448, 'Bortezomib', 'Liver Diseases', 'Cases of acute liver failure and other hepatic reactions such as hepatitis, increases in liver enzymes, and hyperbilirubinemia have been reported in patients receiving bortezomib.  Monitoring is recommended and caution should be used when using bortezomib in patients with hepatic impairment.  The exposure of bortezomib is increased in patients with moderate and severe hepatic impairment, and starting dose should be reduced in those patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33604, 24477, 'Bortezomib', 'Liver Diseases', 'Cases of acute liver failure and other hepatic reactions such as hepatitis, increases in liver enzymes, and hyperbilirubinemia have been reported in patients receiving bortezomib.  Monitoring is recommended and caution should be used when using bortezomib in patients with hepatic impairment.  The exposure of bortezomib is increased in patients with moderate and severe hepatic impairment, and starting dose should be reduced in those patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33605, 29074, 'Bortezomib', 'Liver Diseases', 'Cases of acute liver failure and other hepatic reactions such as hepatitis, increases in liver enzymes, and hyperbilirubinemia have been reported in patients receiving bortezomib.  Monitoring is recommended and caution should be used when using bortezomib in patients with hepatic impairment.  The exposure of bortezomib is increased in patients with moderate and severe hepatic impairment, and starting dose should be reduced in those patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33606, 29075, 'Bortezomib', 'Liver Diseases', 'Cases of acute liver failure and other hepatic reactions such as hepatitis, increases in liver enzymes, and hyperbilirubinemia have been reported in patients receiving bortezomib.  Monitoring is recommended and caution should be used when using bortezomib in patients with hepatic impairment.  The exposure of bortezomib is increased in patients with moderate and severe hepatic impairment, and starting dose should be reduced in those patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33607, 5164, 'Bortezomib', 'Hypotension', 'There was an incidence of 8% of hypotension in patients receiving bortezomib therapy.  Caution should be used when treating patients with history of hypotension, syncope, dehydration, or taking antihypertensive medication.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33608, 15448, 'Bortezomib', 'Hypotension', 'There was an incidence of 8% of hypotension in patients receiving bortezomib therapy.  Caution should be used when treating patients with history of hypotension, syncope, dehydration, or taking antihypertensive medication.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33609, 24477, 'Bortezomib', 'Hypotension', 'There was an incidence of 8% of hypotension in patients receiving bortezomib therapy.  Caution should be used when treating patients with history of hypotension, syncope, dehydration, or taking antihypertensive medication.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33610, 29074, 'Bortezomib', 'Hypotension', 'There was an incidence of 8% of hypotension in patients receiving bortezomib therapy.  Caution should be used when treating patients with history of hypotension, syncope, dehydration, or taking antihypertensive medication.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33611, 29075, 'Bortezomib', 'Hypotension', 'There was an incidence of 8% of hypotension in patients receiving bortezomib therapy.  Caution should be used when treating patients with history of hypotension, syncope, dehydration, or taking antihypertensive medication.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33612, 5164, 'Bortezomib', 'Peripheral Nervous System Diseases', 'Bortezomib can cause peripheral neuropathy that is predominantly sensory; however cases of severe sensory and motor peripheral neuropathy have been also reported.  Patients with preexisting symptoms (numbness, pain or burning feeling in hands or feet) may experience worsening symptoms during treatment.  Patients should be monitored for symptoms of neuropathy, and a dose adjustment might be required in those patients that experience them.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33613, 15448, 'Bortezomib', 'Peripheral Nervous System Diseases', 'Bortezomib can cause peripheral neuropathy that is predominantly sensory; however cases of severe sensory and motor peripheral neuropathy have been also reported.  Patients with preexisting symptoms (numbness, pain or burning feeling in hands or feet) may experience worsening symptoms during treatment.  Patients should be monitored for symptoms of neuropathy, and a dose adjustment might be required in those patients that experience them.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33614, 24477, 'Bortezomib', 'Peripheral Nervous System Diseases', 'Bortezomib can cause peripheral neuropathy that is predominantly sensory; however cases of severe sensory and motor peripheral neuropathy have been also reported.  Patients with preexisting symptoms (numbness, pain or burning feeling in hands or feet) may experience worsening symptoms during treatment.  Patients should be monitored for symptoms of neuropathy, and a dose adjustment might be required in those patients that experience them.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33615, 29074, 'Bortezomib', 'Peripheral Nervous System Diseases', 'Bortezomib can cause peripheral neuropathy that is predominantly sensory; however cases of severe sensory and motor peripheral neuropathy have been also reported.  Patients with preexisting symptoms (numbness, pain or burning feeling in hands or feet) may experience worsening symptoms during treatment.  Patients should be monitored for symptoms of neuropathy, and a dose adjustment might be required in those patients that experience them.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33616, 29075, 'Bortezomib', 'Peripheral Nervous System Diseases', 'Bortezomib can cause peripheral neuropathy that is predominantly sensory; however cases of severe sensory and motor peripheral neuropathy have been also reported.  Patients with preexisting symptoms (numbness, pain or burning feeling in hands or feet) may experience worsening symptoms during treatment.  Patients should be monitored for symptoms of neuropathy, and a dose adjustment might be required in those patients that experience them.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33617, 5164, 'Bortezomib', 'Lung Diseases', 'There have been reports of Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology in patients receiving bortezomib.  Additionally, there have been reports of pulmonary hypertension associated with bortezomib administration in the absence of left heart failure or significant pulmonary disease.  Treatment interruption should be considered in the event of new or worsening cardiopulmonary symptoms until a comprehensive diagnostic evaluation is conducted.  Caution should be exercised when using bortezomib in patients with cardiopulmonary pathologies.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33618, 15448, 'Bortezomib', 'Lung Diseases', 'There have been reports of Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology in patients receiving bortezomib.  Additionally, there have been reports of pulmonary hypertension associated with bortezomib administration in the absence of left heart failure or significant pulmonary disease.  Treatment interruption should be considered in the event of new or worsening cardiopulmonary symptoms until a comprehensive diagnostic evaluation is conducted.  Caution should be exercised when using bortezomib in patients with cardiopulmonary pathologies.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33619, 24477, 'Bortezomib', 'Lung Diseases', 'There have been reports of Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology in patients receiving bortezomib.  Additionally, there have been reports of pulmonary hypertension associated with bortezomib administration in the absence of left heart failure or significant pulmonary disease.  Treatment interruption should be considered in the event of new or worsening cardiopulmonary symptoms until a comprehensive diagnostic evaluation is conducted.  Caution should be exercised when using bortezomib in patients with cardiopulmonary pathologies.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33620, 29074, 'Bortezomib', 'Lung Diseases', 'There have been reports of Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology in patients receiving bortezomib.  Additionally, there have been reports of pulmonary hypertension associated with bortezomib administration in the absence of left heart failure or significant pulmonary disease.  Treatment interruption should be considered in the event of new or worsening cardiopulmonary symptoms until a comprehensive diagnostic evaluation is conducted.  Caution should be exercised when using bortezomib in patients with cardiopulmonary pathologies.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33621, 29075, 'Bortezomib', 'Lung Diseases', 'There have been reports of Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology in patients receiving bortezomib.  Additionally, there have been reports of pulmonary hypertension associated with bortezomib administration in the absence of left heart failure or significant pulmonary disease.  Treatment interruption should be considered in the event of new or worsening cardiopulmonary symptoms until a comprehensive diagnostic evaluation is conducted.  Caution should be exercised when using bortezomib in patients with cardiopulmonary pathologies.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33622, 15449, 'Bosentan', 'Liver Failure', 'Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure.  Hepatic function should be assessed before treatment initiation and closely monitored during treatment.  Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice.  Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult.  In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33623, 15450, 'Bosentan', 'Liver Failure', 'Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure.  Hepatic function should be assessed before treatment initiation and closely monitored during treatment.  Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice.  Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult.  In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33624, 25484, 'Bosentan', 'Liver Failure', 'Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure.  Hepatic function should be assessed before treatment initiation and closely monitored during treatment.  Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice.  Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult.  In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33625, 15449, 'Bosentan', 'Anemia', 'Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels.  There are some postmarketing reports of anemia cases which needed blood transfusion.  Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter.  Initiation of therapy is not recommended in patients with clinically significant anemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33626, 15450, 'Bosentan', 'Anemia', 'Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels.  There are some postmarketing reports of anemia cases which needed blood transfusion.  Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter.  Initiation of therapy is not recommended in patients with clinically significant anemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33627, 25484, 'Bosentan', 'Anemia', 'Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels.  There are some postmarketing reports of anemia cases which needed blood transfusion.  Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter.  Initiation of therapy is not recommended in patients with clinically significant anemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33628, 15449, 'Bosentan', 'Water-Electrolyte Imbalance', 'Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists.  Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33629, 15450, 'Bosentan', 'Water-Electrolyte Imbalance', 'Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists.  Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33630, 25484, 'Bosentan', 'Water-Electrolyte Imbalance', 'Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists.  Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33631, 0, 'Bretylium', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33632, 0, 'Bretylium', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33633, 0, 'Bretylium', 'Kidney Diseases', 'Bretylium is primarily eliminated by the kidney.  Approximately 77% of bretylium is excreted in the urine unchanged.  There are no known metabolites of bretylium.  The serum concentration of bretylium is increased and the half-life prolonged in patients with renal impairment.  Therapy with bretylium should be administered cautiously and the dosing interval increased in patients with compromised renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.  Bretylium is moderately removed during hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33634, 0, 'Blinatumomab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33635, 0, 'Blinatumomab', 'Cardiovascular Diseases', 'The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.  Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33636, 0, 'Blinatumomab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33637, 0, 'Blinatumomab', 'Liver Diseases', 'The use of blinatumomab has been associated with transient elevations in liver enzymes.  Care should be exercised when using this agent in patients with liver impairment.  It is recommended to monitor liver enzymes before the start of therapy and periodically as clinically appropriate.  Interrupt treatment if the transaminases levels rise to greater than 5 times the upper limit of normal or if bilirubin rises to more than 3 times the upper limit normal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33638, 0, 'Blinatumomab', 'Nervous System Diseases', 'Serious neurological toxicity such as encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders have been reported with the use of blinatumomab therapy.  Monitor therapy closely if administered to patients with or predisposed to neurological impairment and interruption or discontinuation of therapy might be appropriate in some cases.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33639, 0, 'Blinatumomab', 'Neutropenia', 'The use of blinatumomab may cause life-threatening neutropenia, and febrile neutropenia.  It is recommended to monitor complete blood counts during the infusion.  Therapy interruption is recommended for prolonged neutropenia.  Care and close monitoring is recommended, in particular for any episodes of fever.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33640, 0, 'Blinatumomab', 'Pancreatitis', 'Fatal pancreatitis has been observed in patients treated with blinatumomab in combination with dexamethasone.  Care should be exercised when using blinatumomab in combination with dexamethasone in patients with pancreatic disorders.  Management of pancreatitis may require either temporary interruption or discontinuation of these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33641, 0, 'Blinatumomab', 'Kidney Diseases', 'No formal pharmacokinetic studies of blinatumomab have been conducted in patients with renal impairment.  Pharmacokinetic analyses showed an approximately 2-fold difference in mean blinatumomab clearance values between patients with moderate renal impairment (CrCl ranging from 30 to 59 mL/min, N = 21) and normal renal function.  However, high interpatient variability was observed (CV% up to 96.8%), and clearance values in renal impaired patients were essentially within the range observed in patients with normal renal function.  Close monitoring is recommended in patients with severe renal impairment (CrCl less than 30 mL/min) or patients on hemodialysis as there is no information available.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33642, 0, 'Bremelanotide', 'Cardiovascular Diseases', 'Bremelanotide is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease, as it transiently increases blood pressure and reduces heart rate after each dose.  Before initiating bremelanotide, and periodically during treatment, consider the patient''s cardiovascular risk and ensure blood pressure is well-controlled.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33643, 0, 'Bremelanotide', 'Liver Failure', 'Bremelanotide has not been evaluated in patients with severe hepatic impairment and should be used with caution in these patients (Child-Pugh C; score 10-15), because they may have an increase in the incidence and severity of adverse reactions (e.g., nausea and vomiting).  No dosing adjustments are recommended for patients with mild to moderate (Child-Pugh A and B; score 5-9) hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33644, 0, 'Bremelanotide', 'Kidney Failure, Chronic', 'Use bremelanotide with caution in patients with severe (eGFR <30 mL/min/1.73 m2) renal impairment, because these patients may have an increase in the incidence and severity of adverse reactions (e.g., nausea and vomiting).  No dosing adjustments are recommended for patients with mild to moderate (eGFR 30-89 mL/min/1.73 m2) renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33645, 13470, 'Brentuximab vedotin', 'Liver Diseases', 'The use of brentuximab vedotin should be avoided in patients with moderate or severe hepatic impairment.  Serious cases of hepatotoxicities have occurred in patients receiving this agent.  Patients with preexisting liver disease, and those with elevated baseline liver enzymes may be at an increased risk.  Monitor liver enzymes and bilirubin.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33646, 13470, 'Brentuximab vedotin', 'Infections', 'Serious infections, including opportunistic infections have been reported with the use of brentuximab vedotin.  Monitor patients closely for the development of any infection during treatment with this agent.  JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with this agent.  A diagnosis of PML should be considered in any patient presenting with new-onset of neurological manifestations and a consultation with a neurologist is recommended.  Hold therapy for any suspected case of PML and discontinue if a diagnosis of PML is confirmed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33647, 13470, 'Brentuximab vedotin', 'Kidney Diseases', 'The frequency of adverse reactions, including fatalities are increased in patients with severe renal impairment.  It is recommended to avoid the use of this agent in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33648, 13470, 'Brentuximab vedotin', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33649, 13470, 'Brentuximab vedotin', 'Neutropenia', 'Hematological toxicities, including prolonged severe neutropenia, thrombocytopenia or anemia can occur with the use of brentuximab vedotin.  It is recommended to monitor patients for fever and if appropriate, dose delays, reduction, or discontinuation of treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33650, 13470, 'Brentuximab vedotin', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy, predominantly sensory neuropathy has occurred in patients treated with brentuximab vedotin.  It is recommended to monitor patients for symptoms of neuropathy and in those experiencing new or worsening peripheral neuropathy.  It is recommended to delay, or change dosage, or discontinue treatment as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33651, 13470, 'Brentuximab vedotin', 'Lung Diseases', 'Cases of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported with the use of brentuximab vedotin.  Care should be taken when using this agent in patients at risk of pulmonary events.  Hold dose in the event of new or worsening of pulmonary complications until symptoms improve.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33652, 13470, 'Brentuximab vedotin', 'Digestive System Diseases', 'Cases of fatal and serious gastrointestinal complication have been reported with the use of brentuximab vedotin.  Care should be taken when using this agent in patients with a history of gastrointestinal complications, as its use can increase the risk of perforation.  Closely monitor for new or worsening of GI symptoms and treat according to clinical practices.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33653, 53, 'Biperiden', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33654, 236, 'Biperiden', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33655, 238, 'Biperiden', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33656, 1586, 'Biperiden', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33657, 1888, 'Biperiden', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33658, 6942, 'Biperiden', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33659, 13599, 'Biperiden', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33660, 53, 'Biperiden', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33661, 236, 'Biperiden', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33662, 238, 'Biperiden', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33663, 1586, 'Biperiden', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33664, 1888, 'Biperiden', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33665, 6942, 'Biperiden', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33666, 13599, 'Biperiden', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33667, 53, 'Biperiden', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33668, 236, 'Biperiden', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33669, 238, 'Biperiden', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33670, 1586, 'Biperiden', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33671, 1888, 'Biperiden', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33672, 6942, 'Biperiden', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33673, 13599, 'Biperiden', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33674, 53, 'Biperiden', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33675, 236, 'Biperiden', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33676, 238, 'Biperiden', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33677, 1586, 'Biperiden', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33678, 1888, 'Biperiden', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33679, 6942, 'Biperiden', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33680, 13599, 'Biperiden', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33681, 53, 'Biperiden', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33682, 236, 'Biperiden', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33683, 238, 'Biperiden', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33684, 1586, 'Biperiden', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33685, 1888, 'Biperiden', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33686, 6942, 'Biperiden', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33687, 13599, 'Biperiden', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33688, 53, 'Biperiden', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33689, 236, 'Biperiden', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33690, 238, 'Biperiden', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33691, 1586, 'Biperiden', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33692, 1888, 'Biperiden', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33693, 6942, 'Biperiden', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33694, 13599, 'Biperiden', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33695, 53, 'Biperiden', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33696, 236, 'Biperiden', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33697, 238, 'Biperiden', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33698, 1586, 'Biperiden', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33699, 1888, 'Biperiden', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33700, 6942, 'Biperiden', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
